AAPL332.27+5.70 (+1.75%) ▲|ABBV257.12+2.12 (+0.83%) ▲|ABT101.95-1.41 (-1.36%) ▼|ACN183.90+5.99 (+3.37%) ▲|ADBE252.23+3.40 (+1.37%) ▲|AMAT456.49+2.48 (+0.55%) ▲|AMD516.13+12.53 (+2.49%) ▲|AMGN377.35-5.12 (-1.34%) ▼|AMT177.85+4.87 (+2.82%) ▲|AMZN256.78+4.89 (+1.94%) ▲|AVGO361.99+1.16 (+0.32%) ▲|AXP324.69+3.98 (+1.24%) ▲|BA210.45+5.65 (+2.76%) ▲|BAC62.69+0.13 (+0.21%) ▲|BKNG173.92+0.01 (+0.01%) ▲|BLK1,079.65+17.25 (+1.62%) ▲|BMY63.64-0.11 (-0.17%) ▼|BNY162.66+0.07 (+0.04%) ▲|BRK-B510.37+3.37 (+0.66%) ▲|C138.82+0.32 (+0.23%) ▲|CAT818.57+13.57 (+1.69%) ▲|CL86.80-1.10 (-1.25%) ▼|CMCSA25.20+0.03 (+0.12%) ▲|COF208.30+1.19 (+0.57%) ▲|COP137.35+0.31 (+0.23%) ▲|COST904.77+2.39 (+0.26%) ▲|CRM247.72+4.72 (+1.94%) ▲|CSCO112.13+4.69 (+4.37%) ▲|CVS94.66-0.63 (-0.66%) ▼|CVX214.06+1.30 (+0.61%) ▲|DE675.74-2.20 (-0.32%) ▼|DHR200.14-0.39 (-0.19%) ▼|DIS106.55+0.73 (+0.69%) ▲|DUK119.42+0.05 (+0.04%) ▲|EMR152.19+3.82 (+2.57%) ▲|FDX311.99+0.19 (+0.06%) ▲|GD355.90+1.65 (+0.47%) ▲|GE323.66-0.49 (-0.15%) ▼|GEV957.27+33.36 (+3.61%) ▲|GILD143.72-1.09 (-0.75%) ▼|GM85.62-0.50 (-0.58%) ▼|GOOG335.45+5.06 (+1.53%) ▲|GOOGL338.50+5.90 (+1.77%) ▲|GS1,029.18+9.41 (+0.92%) ▲|HD308.74+3.05 (+1.00%) ▲|HON202.36+0.18 (+0.09%) ▲|IBM243.29+9.27 (+3.96%) ▲|INTC102.94+2.62 (+2.61%) ▲|INTU321.57+8.80 (+2.81%) ▲|ISRG369.15+8.69 (+2.41%) ▲|JNJ265.58-0.77 (-0.29%) ▼|JPM356.23+2.67 (+0.76%) ▲|KO88.29+0.46 (+0.52%) ▲|LIN466.22+4.60 (+1.00%) ▲|LLY1,115.70-7.30 (-0.65%) ▼|LMT524.19-5.93 (-1.12%) ▼|LOW196.82+0.23 (+0.12%) ▲|LRCX298.22+0.21 (+0.07%) ▲|MA569.19+3.82 (+0.68%) ▲|MCD252.53-0.52 (-0.21%) ▼|MDLZ62.44-0.03 (-0.05%) ▼|MDT90.96-0.66 (-0.72%) ▼|META648.03+3.65 (+0.57%) ▲|MMM164.97+2.11 (+1.30%) ▲|MO68.98+0.19 (+0.28%) ▲|MRK143.93-0.78 (-0.54%) ▼|MS214.38+1.72 (+0.81%) ▲|MSFT495.63+3.19 (+0.65%) ▲|MU975.26-2.15 (-0.22%) ▼|NEE82.31-0.13 (-0.16%) ▼|NFLX77.40+1.39 (+1.83%) ▲|NKE36.80+0.18 (+0.49%) ▲|NOW132.53+1.36 (+1.04%) ▲|NVDA218.29-0.07 (-0.03%) ▼|ORCL150.28-2.66 (-1.74%) ▼|PEP136.32-0.33 (-0.24%) ▼|PFE27.72+0.07 (+0.25%) ▲|PG145.27+2.30 (+1.61%) ▲|PLTR167.23+1.37 (+0.83%) ▲|PM191.06+1.29 (+0.68%) ▲|QCOM181.97+5.09 (+2.88%) ▲|RTX197.68-0.44 (-0.22%) ▼|SBUX98.74-0.48 (-0.48%) ▼|SCHW107.25-0.08 (-0.07%) ▼|SO87.17-0.58 (-0.66%) ▼|SPG204.83+0.16 (+0.08%) ▲|T26.06+0.51 (+2.00%) ▲|TMO609.82+6.64 (+1.10%) ▲|TMUS182.33+5.17 (+2.92%) ▲|TSLA365.44+1.88 (+0.52%) ▲|TXN268.70+9.88 (+3.82%) ▲|UBER71.67-0.89 (-1.23%) ▼|UNH379.09-9.19 (-2.37%) ▼|UNP284.40-1.38 (-0.48%) ▼|UPS100.28+0.31 (+0.31%) ▲|USB62.84+0.43 (+0.69%) ▲|V370.45+3.24 (+0.88%) ▲|VZ50.61+0.64 (+1.28%) ▲|WFC90.29+0.84 (+0.94%) ▲|WMT107.15+1.42 (+1.34%) ▲|XOM165.99+0.76 (+0.46%) ▲|AAPL332.27+5.70 (+1.75%) ▲|ABBV257.12+2.12 (+0.83%) ▲|ABT101.95-1.41 (-1.36%) ▼|ACN183.90+5.99 (+3.37%) ▲|ADBE252.23+3.40 (+1.37%) ▲|AMAT456.49+2.48 (+0.55%) ▲|AMD516.13+12.53 (+2.49%) ▲|AMGN377.35-5.12 (-1.34%) ▼|AMT177.85+4.87 (+2.82%) ▲|AMZN256.78+4.89 (+1.94%) ▲|AVGO361.99+1.16 (+0.32%) ▲|AXP324.69+3.98 (+1.24%) ▲|BA210.45+5.65 (+2.76%) ▲|BAC62.69+0.13 (+0.21%) ▲|BKNG173.92+0.01 (+0.01%) ▲|BLK1,079.65+17.25 (+1.62%) ▲|BMY63.64-0.11 (-0.17%) ▼|BNY162.66+0.07 (+0.04%) ▲|BRK-B510.37+3.37 (+0.66%) ▲|C138.82+0.32 (+0.23%) ▲|CAT818.57+13.57 (+1.69%) ▲|CL86.80-1.10 (-1.25%) ▼|CMCSA25.20+0.03 (+0.12%) ▲|COF208.30+1.19 (+0.57%) ▲|COP137.35+0.31 (+0.23%) ▲|COST904.77+2.39 (+0.26%) ▲|CRM247.72+4.72 (+1.94%) ▲|CSCO112.13+4.69 (+4.37%) ▲|CVS94.66-0.63 (-0.66%) ▼|CVX214.06+1.30 (+0.61%) ▲|DE675.74-2.20 (-0.32%) ▼|DHR200.14-0.39 (-0.19%) ▼|DIS106.55+0.73 (+0.69%) ▲|DUK119.42+0.05 (+0.04%) ▲|EMR152.19+3.82 (+2.57%) ▲|FDX311.99+0.19 (+0.06%) ▲|GD355.90+1.65 (+0.47%) ▲|GE323.66-0.49 (-0.15%) ▼|GEV957.27+33.36 (+3.61%) ▲|GILD143.72-1.09 (-0.75%) ▼|GM85.62-0.50 (-0.58%) ▼|GOOG335.45+5.06 (+1.53%) ▲|GOOGL338.50+5.90 (+1.77%) ▲|GS1,029.18+9.41 (+0.92%) ▲|HD308.74+3.05 (+1.00%) ▲|HON202.36+0.18 (+0.09%) ▲|IBM243.29+9.27 (+3.96%) ▲|INTC102.94+2.62 (+2.61%) ▲|INTU321.57+8.80 (+2.81%) ▲|ISRG369.15+8.69 (+2.41%) ▲|JNJ265.58-0.77 (-0.29%) ▼|JPM356.23+2.67 (+0.76%) ▲|KO88.29+0.46 (+0.52%) ▲|LIN466.22+4.60 (+1.00%) ▲|LLY1,115.70-7.30 (-0.65%) ▼|LMT524.19-5.93 (-1.12%) ▼|LOW196.82+0.23 (+0.12%) ▲|LRCX298.22+0.21 (+0.07%) ▲|MA569.19+3.82 (+0.68%) ▲|MCD252.53-0.52 (-0.21%) ▼|MDLZ62.44-0.03 (-0.05%) ▼|MDT90.96-0.66 (-0.72%) ▼|META648.03+3.65 (+0.57%) ▲|MMM164.97+2.11 (+1.30%) ▲|MO68.98+0.19 (+0.28%) ▲|MRK143.93-0.78 (-0.54%) ▼|MS214.38+1.72 (+0.81%) ▲|MSFT495.63+3.19 (+0.65%) ▲|MU975.26-2.15 (-0.22%) ▼|NEE82.31-0.13 (-0.16%) ▼|NFLX77.40+1.39 (+1.83%) ▲|NKE36.80+0.18 (+0.49%) ▲|NOW132.53+1.36 (+1.04%) ▲|NVDA218.29-0.07 (-0.03%) ▼|ORCL150.28-2.66 (-1.74%) ▼|PEP136.32-0.33 (-0.24%) ▼|PFE27.72+0.07 (+0.25%) ▲|PG145.27+2.30 (+1.61%) ▲|PLTR167.23+1.37 (+0.83%) ▲|PM191.06+1.29 (+0.68%) ▲|QCOM181.97+5.09 (+2.88%) ▲|RTX197.68-0.44 (-0.22%) ▼|SBUX98.74-0.48 (-0.48%) ▼|SCHW107.25-0.08 (-0.07%) ▼|SO87.17-0.58 (-0.66%) ▼|SPG204.83+0.16 (+0.08%) ▲|T26.06+0.51 (+2.00%) ▲|TMO609.82+6.64 (+1.10%) ▲|TMUS182.33+5.17 (+2.92%) ▲|TSLA365.44+1.88 (+0.52%) ▲|TXN268.70+9.88 (+3.82%) ▲|UBER71.67-0.89 (-1.23%) ▼|UNH379.09-9.19 (-2.37%) ▼|UNP284.40-1.38 (-0.48%) ▼|UPS100.28+0.31 (+0.31%) ▲|USB62.84+0.43 (+0.69%) ▲|V370.45+3.24 (+0.88%) ▲|VZ50.61+0.64 (+1.28%) ▲|WFC90.29+0.84 (+0.94%) ▲|WMT107.15+1.42 (+1.34%) ▲|XOM165.99+0.76 (+0.46%) ▲|
22.5 C
New York
Saturday, September 12, 2026

Tag: treatments

newssourceFORcompanyinformationcontent1releasesmarket

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are...

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are...

Cancer Therapeutics Market Forecast to Reach $168 Billion by 2029, Highlighting Recurrent and Metastatic Innovations

"Metastatic Cancer: A Significant Therapeutic Challenge as Pharmaceutical Companies Leverage Digital Platforms and Data to Enhance Engagement with Patients, Providers, and Regulators in the...

Oncology Innovation Just Hit a Turning Point — Here’s What to Watch

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape...

Finding Suggests Treatment Approach for Autoimmune Diseases

NEW YORK, June 30, 2025 /PRNewswire/ -- An engineered protein turns off the kind of immune cells most likely to damage tissue as part...

Oncology Innovation Just Hit a Turning Point — Here’s What to Watch

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape...

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure.

InterShunt Enrolls First Patient in New Heart Failure Study

Innovative procedure aims to ease symptoms and reduce hospitalizations MINNEAPOLIS, June 30, 2025 /PRNewswire/ -- InterShunt Technologies, Inc., a medical device company focused on...

Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan

Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency...

Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan

Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency...

Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan

Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency...

Affidea Group selects b-rayZ as its preferred AI partner in breast imaging, marking strategic collaboration

THE HAGUE, The Netherlands, June 30, 2025 (GLOBE NEWSWIRE) -- In a strategic move to improve patient outcomes in breast cancer, Affidea, a leading pan-European provider of community-based polyclinics, specialist services and advanced diagnostics, is proud to announce that it has selected b-rayZ, a leader in AI-powered breast imaging solutions, as its preferred AI partner for breast imaging.

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatments

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers